Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-723 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70589 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4742 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 |
filingDate |
2016-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2018-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2018511651-A |
titleOfInvention |
Use of cabazitaxel in the treatment of prostate cancer |
abstract |
The present invention relates to cabazitaxel for use in a method for treating an AR-V7 positive patient suffering from prostate cancer comprising determining an AR-V7 status in a patient and administering cabazitaxel. . The invention also includes a method of identifying a prostate cancer patient eligible for treatment with cabazitaxel, comprising examining a biological sample from the patient for the presence of AR-V7 in circulating tumor cells, If the circulating tumor cell result is positive for AR-V7, the patient is eligible for treatment with said cabazitaxel. The invention further relates to a parts kit for determining AR-V7 status in isolated tumor cells of prostate cancer patients. |
priorityDate |
2015-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |